DOXORUBICIN CARDIOMYOPATHY IS ASSOCIATED WITH A DECREASE IN CALCIUM RELEASE CHANNEL OF THE SARCOPLASMIC-RETICULUM IN A CHRONIC RABBIT MODEL

被引:94
作者
DODD, DA
ATKINSON, JB
OLSON, RD
BUCK, S
CUSACK, BJ
FLEISCHER, S
BOUCEK, RJ
机构
[1] VET ADM, DEPT PHARMACOL, BOISE, ID 83702 USA
[2] VANDERBILT UNIV, MED CTR, DEPT PATHOL, NASHVILLE, TN 37232 USA
[3] VANDERBILT UNIV, MED CTR, DEPT MOLEC BIOL, NASHVILLE, TN 37232 USA
[4] VANDERBILT UNIV, MED CTR, DEPT BIOCHEM, NASHVILLE, TN 37232 USA
关键词
BINDING; CARDIAC; CHEMOTHERAPY; RADIOLIGAND; RYANODINE RECEPTOR;
D O I
10.1172/JCI116379
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Doxorubicin is a highly effective cancer chemotherapeutic agent that produces a dose-dependent cardiomyopathy that limits its clinical usefulness. Clinical and animal studies of morphological changes during the early stages of doxorubicin-induced cardiomyopathy have suggested that the sarcoplasmic reticulum, the intracellular membrane system responsible for myoplasmic calcium regulation in adult mammalian heart, may be the early target of doxorubicin. To detect changes in the calcium pump protein or the calcium release channel (ryanodine receptor) of the sarcoplasmic reticulum during chronic doxorubicin treatment, rabbits were treated with intravenous doxorubicin (1 mg/kg) twice weekly for 12 to 18 doses. Pair-fed controls received intravenous normal saline. The severity of cardiomyopathy was scored by light and electron microscopy of left ventricular papillary muscles. Developed tension was measured in isolated atrial strips. In subcellular fractions from heart, [H-3]ryanodine binding was decreased in doxorubicin-treated rabbits (0.33+/-0.03 pmol/mg) compared with control rabbits (0.66+/-0.02 pmol/mg; P < 0.0001). The magnitude of the decrease in [H-3]ryanodine binding correlated with both the severity of the cardiomyopathy graded by pathology score (light and electron microscopy) and the decrease in developed tension in isolated atrial strips. B(max) for [H-3]ryanodine binding and the amount of immunoreactive ryanodine receptor by Western blot analysis using sequence-specific antibody were both decreased, consistent with a decrease in the amount of calcium release channel of sarcoplasmic reticulum in doxorubicin-treated rabbits. In contrast, there was no decrease in the amount or the activity of the calcium pump protein of the sarcoplasmic reticulum in doxorubicin-treated rabbits. Doxorubicin treatment did not decrease [H-3]ryanodine binding or the amount of immunoreactive calcium release channel of sarcoplasmic reticulum in skeletal muscle. Since the sarcoplasmic reticulum regulates muscle contraction by the cyclic uptake and release of a large internal calcium pool, altered function of the calcium release channel could lead to the abnormalities of contraction and relaxation observed in the doxorubicin cardiomyopathy.
引用
收藏
页码:1697 / 1705
页数:9
相关论文
共 61 条
[1]  
ABRAMSON JJ, 1988, J BIOL CHEM, V263, P18750
[2]   CRITICAL SULFHYDRYLS REGULATE CALCIUM RELEASE FROM SARCOPLASMIC-RETICULUM [J].
ABRAMSON, JJ ;
SALAMA, G .
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 1989, 21 (02) :283-294
[3]   ADRIAMYCIN CARDIOMYOPATHY IN THE RABBIT - AN ANIMAL-MODEL OF LOW OUTPUT CARDIAC-FAILURE WITH ACTIVATION OF VASOCONSTRICTOR MECHANISMS [J].
ARNOLDA, L ;
MCGRATH, B ;
COCKS, M ;
SUMITHRAN, E ;
JOHNSTON, C .
CARDIOVASCULAR RESEARCH, 1985, 19 (06) :378-382
[4]  
BACHUR NR, 1974, J PHARMACOL EXP THER, V191, P331
[5]   EARLY AND LATE SARCOPLASMIC-RETICULUM CHANGES IN DOXORUBICIN CARDIOMYOPATHY - AN ULTRASTRUCTURAL INVESTIGATION WITH THE ZINC IODIDE-OSMIUM TETROXIDE (ZIO) TECHNIQUE [J].
BELLINI, O ;
SOLCIA, E .
VIRCHOWS ARCHIV B-CELL PATHOLOGY INCLUDING MOLECULAR PATHOLOGY, 1985, 49 (02) :137-152
[6]  
Billingham M, 1991, CARDIOVASC PATHOL, P1465
[7]  
BOUCEK RJ, 1987, J BIOL CHEM, V262, P15851
[8]  
BRISTOW MR, 1978, CANCER TREAT REP, V62, P873
[9]   ISOLATION AND CHARACTERIZATION OF THE INOSITOL TRISPHOSPHATE RECEPTOR FROM SMOOTH-MUSCLE [J].
CHADWICK, CC ;
SAITO, A ;
FLEISCHER, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (06) :2132-2136
[10]  
CHAMBERLAIN BK, 1988, METHOD ENZYMOL, V157, P91